Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07517263 · ClinicalTrials.gov registry record · Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,700
- Enrollment target
NCT07517263 is a Phase 3 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 5,700 participants.
The verdict
NCT07517263, a Phase 3 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,700 participants
- Enrollment target
Study Summary
This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
Interventions
- DRUG Pelacarsen (TQJ230)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,700 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2030-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07517263
The ClinicalTrials.gov registry entry for NCT07517263 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pelacarsen (TQJ230) is the first listed.
NCT07517263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07517263 about?
NCT07517263 is a clinical study titled "An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)". This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
What is the current status of trial NCT07517263?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,700 participants. The study started on 2026-05-11. Estimated completion is 2030-01-09.
What interventions are being tested in trial NCT07517263?
The interventions under investigation include: Pelacarsen (TQJ230) (DRUG).
Who is sponsoring clinical trial NCT07517263?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.